Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
Paris, May 14, 2020 – The French company specialized in MedTech, PKvitality, is the first to be accelerated by Dassault Systèmes’ 3DEXPERIENCE Lab and accompanied by Sanofi’s 39bis innovation laboratory. The two experts have joined forces to nurture promising start-ups with the aim of improving the patient experience using digital health technologies. PKvitality is developing K’Watch, a Continuous Glucose Monitor (CGM) in a form of a smartwatch.
Dassault Systèmes’ 3DEXPERIENCE Lab is an open innovation laboratory and accelerator program dedicated to nurturing and empowering disruptive projects that have the potential to transform society. Sanofi is one of the world leaders in the healthcare sector and specializes in pharmaceuticals and vaccines. These two entities have coupled their expertise to co-accelerate start-ups from around the world. The aim is to foster the creation of new therapeutic solutions, help accelerate their product development, and reduce their time to market.
“We are honoured to be the first in a long list of exciting partnerships to come. We believe that these collaborations between startups and leaders of the market will greatly benefit the market in terms of innovation, speed and quality of execution.” said Luc Piérart, CEO of PKvitality.
Being the first company to be accelerated by Dassault Systèmes’ 3DEXPERIENCE Lab and accompanied by Sanofi’s 39bis innovation laboratory gives PKvitality access to a full technology, mentoring and networking support system to enhance the development of its project including training and coaching from a community of experts. PKvitality also gains access to Dassault Systèmes’ 3DEXPERIENCE platform and receives valuable support in simulation and QMS.
Dassault Systèmes’s 3DEXPERIENCE Lab will also act as a business accelerator, supporting PKvitality with marketing and communication of the K’Watch project. This support gives PKvitality access to a much wider network of potential partners and investors, as well as medical experts.
PKvitality is an advanced bio-wearable start-up currently working on K’Watch, a painless and discreet Continuous Glucose Monitoring (CGM) device in the form of a smartwatch. It will enable a precise and continuous monitoring of systemic glucose level anytime and anywhere. Using the same technology, PKvitality is also working on K’Watch Athlete, a smartwatch which will provide real-time monitoring of their lactic acid – an indicator of muscle fatigue – to significantly improve an athlete’s training and performance. For more information, visit www.PKvitality.com
K’Watch will be the first Continuous Glucose Monitor in the form of a smartwatch. It is composed of two parts: K’Watch, the smartwatch and K’apsul, an adhesive patch at the back. It enables a precise and continuous monitoring of systemic glucose levels anytime and anywhere. This is possible thanks to SkinTaste®, a patented biosensor array that uses micropoints (<1mm long) in order to analyse chemical compositions of the interstitial fluid. Completely invisible to others, the diabetic patient can check its level discreetly and be alerted by an on-body vibration of hypo and hyperglycemia episodes to come.
Minh Lê firstname.lastname@example.org